NeuroSense Therapeutics Ltd.

NRSNNASDAQHealthcare● Active

$0.75

+$0.00(+0.20%)

Market Cap$18539466

P/E Ratio—

52W High$2.6

52W Low$0.63

Avg Volume152K

Open$0.77

Beta1.54

Revenue Financials Earnings

NeuroSense Therapeutics Ltd. (NRSN) Revenue

Annual & quarterly revenue history · segment & region breakdown

NRSN · revenue · updated Jun 9, 2026

Core revenue metrics

Trailing 12 months

NeuroSense Therapeutics Ltd. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY2025 $0.00B

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

17 employees

FY2025

$0.00B

FY2024

$0.00B

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · NeuroSense Therapeutics Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

2025 – 2019 · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth
2025-12-31	$0.00B	+$0.00B	—
2024-12-31	$0.00B	+$0.00B	—
2023-12-31	$0.00B	+$0.00B	—
2022-12-31	$0.00B	+$0.00B	—
2021-12-31	$0.00B	+$0.00B	—
2020-12-31	$0.00B	+$0.00B	—
2019-12-31	$0.00B	—	—

NRSN revenue by year · NRSN revenue history · NRSN annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income NeuroSense Therapeutics Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

NeuroSense Therapeutics Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from NeuroSense Therapeutics Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

NRSN revenue · 4 questions

NRSN's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.

NRSN revenueNRSN annual revenuewhat is NRSN revenueNRSN TTM revenue

▸ Source: FMP · NeuroSense Therapeutics Ltd. SEC filings · GAAP · NeuroSense Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026